288 related articles for article (PubMed ID: 22991313)
21. Teriparatide for severe osteoporosis.
Cappuzzo KA; Delafuente JC
Ann Pharmacother; 2004 Feb; 38(2):294-302. PubMed ID: 14742769
[TBL] [Abstract][Full Text] [Related]
22. Descriptive epidemiology of malignant primary osteosarcoma using population-based registries, United States, 1999-2008.
Duong LM; Richardson LC
J Registry Manag; 2013; 40(2):59-64. PubMed ID: 24002129
[TBL] [Abstract][Full Text] [Related]
23. Teriparatide for postmenopausal osteoporosis.
Drug Ther Bull; 2004 Dec; 42(12):93-5. PubMed ID: 15587764
[TBL] [Abstract][Full Text] [Related]
24. A review of teriparatide and its clinical efficacy in the treatment of osteoporosis.
Dobnig H
Expert Opin Pharmacother; 2004 May; 5(5):1153-62. PubMed ID: 15155114
[TBL] [Abstract][Full Text] [Related]
25. Teriparatide and Osteosarcoma Risk: History, Science, Elimination of Boxed Warning, and Other Label Updates.
Krege JH; Gilsenan AW; Komacko JL; Kellier-Steele N
JBMR Plus; 2022 Sep; 6(9):e10665. PubMed ID: 36111201
[TBL] [Abstract][Full Text] [Related]
26. Compliance and persistence with treatment with parathyroid hormone for osteoporosis. A Danish national register-based cohort study.
Thorsteinsson AL; Vestergaard P; Eiken P
Arch Osteoporos; 2015; 10():35. PubMed ID: 26427867
[TBL] [Abstract][Full Text] [Related]
27. Assessing compliance, acceptance, and tolerability of teriparatide in patients with osteoporosis who fractured while on antiresorptive treatment or were intolerant to previous antiresorptive treatment: an 18-month, multicenter, open-label, prospective study.
Adachi JD; Hanley DA; Lorraine JK; Yu M
Clin Ther; 2007 Sep; 29(9):2055-67. PubMed ID: 18035204
[TBL] [Abstract][Full Text] [Related]
28. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use.
Hodsman AB; Bauer DC; Dempster DW; Dian L; Hanley DA; Harris ST; Kendler DL; McClung MR; Miller PD; Olszynski WP; Orwoll E; Yuen CK
Endocr Rev; 2005 Aug; 26(5):688-703. PubMed ID: 15769903
[TBL] [Abstract][Full Text] [Related]
29. Clinical practice guidelines for the use of parathyroid hormone in the treatment of osteoporosis.
Hodsman A; ; Papaioannou A; ; Ann Cranney ;
CMAJ; 2006 Jul; 175(1):48. PubMed ID: 16818909
[No Abstract] [Full Text] [Related]
30. Present at the beginning: a personal reminiscence on the history of teriparatide.
Marcus R
Osteoporos Int; 2011 Aug; 22(8):2241-8. PubMed ID: 21452026
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.
Henriksen K; Andersen JR; Riis BJ; Mehta N; Tavakkol R; Alexandersen P; Byrjalsen I; Valter I; Nedergaard BS; Teglbjaerg CS; Stern W; Sturmer A; Mitta S; Nino AJ; Fitzpatrick LA; Christiansen C; Karsdal MA
Bone; 2013 Mar; 53(1):160-6. PubMed ID: 23234813
[TBL] [Abstract][Full Text] [Related]
32. The use of PTH in the treatment of osteoporosis.
Borba VZ; Mañas NC
Arq Bras Endocrinol Metabol; 2010 Mar; 54(2):213-9. PubMed ID: 20485911
[TBL] [Abstract][Full Text] [Related]
33. The bone growth-stimulating PTH and osteosarcoma.
Whitfield JF
Medscape Womens Health; 2001 Oct; 6(5):7. PubMed ID: 11698929
[No Abstract] [Full Text] [Related]
34. Teriparatide in individuals with a prior history of radiation therapy-a case series.
Cheung YM; Hamnvik OR
Arch Osteoporos; 2021 Oct; 16(1):149. PubMed ID: 34608566
[TBL] [Abstract][Full Text] [Related]
35. Biologicals in osteoporosis: teriparatide and parathyroid hormone in women and men.
Devogelaer JP; Boutsen Y; Manicourt DH
Curr Osteoporos Rep; 2010 Sep; 8(3):154-61. PubMed ID: 20563900
[TBL] [Abstract][Full Text] [Related]
36. Extremely elevated serum alkaline phosphatase level upon treatment with teriparatide: a case report.
Javinani A; Aghaei Meybodi HR; Kavosi H
J Med Case Rep; 2020 Jul; 14(1):87. PubMed ID: 32616027
[TBL] [Abstract][Full Text] [Related]
37. Acting on black box warnings requires a GRADE evidence table and an implementation guide: the case of teriparatide.
Elraiyah T; Gionfriddo MR; Murad MH
J Clin Epidemiol; 2015 Jun; 68(6):698-702. PubMed ID: 25766055
[TBL] [Abstract][Full Text] [Related]
38. Teriparatide: a review.
Quattrocchi E; Kourlas H
Clin Ther; 2004 Jun; 26(6):841-54. PubMed ID: 15262455
[TBL] [Abstract][Full Text] [Related]
39. Frequency of discontinuation of injectable osteoporosis therapies in US patients over 2 years.
Modi A; Sajjan S; Insinga R; Weaver J; Lewiecki EM; Harris ST
Osteoporos Int; 2017 Apr; 28(4):1355-1363. PubMed ID: 28058444
[TBL] [Abstract][Full Text] [Related]
40. Subungual exostosis in an osteoporotic patient treated with teriparatide.
Delivanis DA; Bhargava A; Luthra P
Endocr Pract; 2013; 19(5):e115-7. PubMed ID: 23757619
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
